References

Pharmacology & Therapeutics 2017;175:133–50. doi:10.1016/j.pharmthera.2017.02.04116. Lu H-C, Mackie K. Review of the endocannabinoid system. Biological Psychiatry: Cognitive Neuroscience and Neuroimaging 2020;:S2451902220302068. doi:10.1016/j.bpsc.2020.07.016

Allan GM, Finley CR, Ton J, et al. Systematic review of systematic reviews for medical cannabinoids: pain, nausea and vomiting, spasticity, and harms. Can Fam Physician 2018;64:e78–94.

Allan GM, Ramji J, Perry D, et al. Simplified guideline for prescribing medical cannabinoids in primary care. Can Fam Physician 2018;64:111–20.

Campbell G, Hall WD, Peacock A, et al. Effect of cannabis use in people with chronic non-cancer pain prescribed opioids: findings from a 4-year prospective cohort study. The Lancet Public Health 2018;3:e341–50. doi:10.1016/ S2468-2667(18)30110-5

Smith LA, Jess CE. Cannabinoids for nausea and vomiting in cancer patients receiving chemotherapy. Cochrane Database of Systematic Reviews 2011;:CD009464. doi:10.1002/14651858.CD009464

Lee Stinnett V, Kuhlmann KL. Cannabinoid Hyperemesis Syndrome: an update for primary care providers. The Journal for Nurse Practitioners 2018;14:450–5. doi:10.1016/j.nurpra.2018.01.020

Zettl UK, Rommer P, Hipp P, et al. Evidence for the efficacy and effectiveness of THC-CBD oromucosal spray in symptom management of patients with spasticity due to multiple sclerosis. Ther Adv Neurol Disord 2016;9:9–30. doi:10.1177/1756285615612659

SATIVEX. Available from: https://www.medsafe.govt.nz/profs/datasheet/s/sativexspray.pdf (Accessed Dec, 2021).

Perucca E. Cannabinoids in the treatment of epilepsy: hard evidence at last? J Epilepsy Res 2017;7:61–76. doi:10.14581/jer.17012

Available from: https://www.health.qld.gov. au/__data/assets/pdf_file/0023/634163/med-cannabis-clinical-guide.pdf (Accessed Dec, 2021).

Pratt M, Stevens A, Thuku M, et al. Benefits and harms of medical cannabis: a scoping review of systematic reviews. Syst Rev 2019;8:320. doi:10.1186/ s13643-019-1243-x

National Academies of Sciences, Engineering, and Medicine (U.S.), editor. The health effects of cannabis and cannabinoids: the current state of evidence and recommendations for research. Washington, DC: The National Academies Press 2017.

Gable RS. Comparison of acute lethal toxicity of commonly abused psychoactive substances. Addiction 2004;99:686–96. doi:10.1111/j.1360-0443.2004.00744.x

Marconi A, Di Forti M, Lewis CM, et al. Meta-analysis of the association between the level of cannabis use and risk of psychosis. SCHBUL 2016;42:1262–9. doi:10.1093/schbul/sbw003

NZF v114. Available from:www.nzf.org.nz(Accessed Dec, 2021).31. Rein JL. The nephrologist’s guide to cannabis and cannabinoids: Current Opinion in Nephrology and Hypertension 2020;29:248–57. doi:10.1097/ MNH.0000000000000590

Available from: https://www.employment.govt.nz/workplace-policies/tests-and-checks/drugs-alcohol-and-work/ (Accessed Dec, 2021).

Available from: https://www.transport.govt.nz/area-of-interest/safety/drug-driving-testing/ (Accessed Dec, 2021).

Interim Report 3 Setting Statutory Limits for Blood Drug Concentrations Relating to Impaired Driving. 2020. Available from: https://www.transport.govt.nz/assets/Uploads/Report/InterimReport3.pdf (Accessed Dec, 2021).

Proposed amendments for the consideration of the Committee of the whole House. 2021. Available from: https://legislation.govt.nz/sop/government/2021/0024/latest/whole.html#COWH378895(Accessed Dec, 2021).

Spindle TR, Cone EJ, Kuntz D, et al. Urinary pharmacokinetic profile of cannabinoids following administration of vaporized and oral cannabidiol and vaporized CBD-dominant cannabis. Journal of Analytical Toxicology 2020;44:109–25. doi:10.1093/jat/bkz080

Lucas CJ, Galettis P, Schneider J. The pharmacokinetics and the pharmacodynamics of cannabinoids. Br J Clin Pharmacol 2018;84:2477–82. doi:10.1111/bcp.13710

Qian Y, Gurley BJ, Markowitz JS. The potential for pharmacokinetic interactions between cannabis products and conventional medications. J Clin Psychopharmacol 2019;39:462–71. doi:10.1097/JCP.0000000000001089

MacCallum CA, Russo EB. Practical considerations in medical cannabis administration and dosing. European Journal of Internal Medicine 2018;49:12–9. doi:10.1016/j.ejim.2018.01.004

Boggs DL, Nguyen JD, Morgenson D, et al. Clinical and preclinical evidence for functional interactions of cannabidiol and Δ9-Tetrahydrocannabinol. Neuropsychopharmacol 2018;43:142–54. doi:10.1038/npp.2017.209

Pellentesque habitant morbi tristique senectus et netus et malesuada fames ac turpis egestas. Vestibulum tortor quam, feugiat vitae, ultricies eget, tempor sit amet, ante. Donec eu libero sit Available from: https://www.health.govt.nz/our-work/regulation-health-and-disability-system/medicinal-cannabis-agency/medicinal-cannabis- agency-information-industry/medicinal-cannabis-agency-working-medicinal- cannabis/medicinal-cannabis-agency-cannabidiol-cbd-products (Accessed Dec, 2021). quam egestas semper. Aenean ultricies mi vitae est. Mauris placerat eleifend leo.